Preeclampsia contributes disproportionately to maternal and neonatal morbidity and mortality throughout the world. A critical driver of preeclampsia is angiogenic imbalance, which is often present weeks to months before overt disease. Two placenta-derived angiogenic biomarkers, soluble fms-like tyrosine kinase 1 (sFlt-1) and placental growth factor (PlGF), have proved useful as diagnostic and prognostic tests for preeclampsia. Recently, the U.S. Food and Drug Administration approved the sFlt-1/PlGF assay to aid in the prediction of preeclampsia with severe features among women with hypertensive disorders of pregnancy at 24-34 weeks of gestation. In this narrative review, we summarize the body of work leading to this approval and describe how the sFlt-1/PlGF ratio may be implemented in clinical practice as an adjunctive measure to help optimize care and to reduce adverse outcomes in preeclampsia.

中文翻译：

---

先兆子痫的血管生成生物标志物。

先兆子痫对全世界孕产妇和新生儿的发病率和死亡率造成不成比例的影响。先兆子痫的一个关键驱动因素是血管生成失衡，这种失衡通常在明显疾病发生前几周至几个月就出现。两种胎盘来源的血管生成生物标志物，可溶性 fms 样酪氨酸激酶 1 (sFlt-1) 和胎盘生长因子 (PlGF)，已被证明可用于先兆子痫的诊断和预后测试。最近，美国食品和药物管理局批准了 sFlt-1/PlGF 检测，以帮助预测妊娠 24-34 周患有妊娠高血压疾病的女性的严重先兆子痫。在这篇叙述性综述中，我们总结了导致此次批准的工作主体，并描述了如何在临床实践中实施 sFlt-1/PlGF 比率作为辅助措施，以帮助优化护理并减少先兆子痫的不良后果。